Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase I for Head And Neck Cancer.

Sparano and co-workers investigated the optimum adjuvant taxane agent and administration schedule in this setting and found that weekly adjuvant paclitaxel therapy after doxorubicin and ...

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544–5552 (2008).

Primary Patency: SIRONA concluded that a primary patency of 73.8% was achieved by MagicTouch PTA against 75% of Paclitaxel ...

The phase III trial, which enrolled 2233 patients, compared two dose-dense chemotherapy regimens: Weekly nab-paclitaxel (125 mg/m 2 for eight cycles) vs biweekly solvent-based paclitaxel (175 mg/m ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

Concept Medical Inc., a global leader in innovative drug-delivery technology having its state-of-the-art manufacturing ...

Immuneering (IMRX) announced a positive data update from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104, ...